HC Wainwright Reiterates “Buy” Rating for Gossamer Bio (NASDAQ:GOSS)

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $10.00 target price on the stock.

Separately, Wedbush restated an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Tuesday, August 13th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Stock Down 1.2 %

GOSS opened at $0.85 on Monday. Gossamer Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.60. The company has a market capitalization of $191.80 million, a P/E ratio of -2.65 and a beta of 1.96. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.21 and a quick ratio of 8.21. The firm’s fifty day moving average price is $0.94 and its two-hundred day moving average price is $0.86.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. The business had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million. On average, analysts anticipate that Gossamer Bio will post -0.33 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of GOSS. SG Americas Securities LLC bought a new position in Gossamer Bio in the 1st quarter valued at $34,000. US Bancorp DE acquired a new stake in shares of Gossamer Bio in the third quarter valued at $39,000. Choreo LLC bought a new position in shares of Gossamer Bio in the second quarter valued at about $46,000. GSA Capital Partners LLP acquired a new position in Gossamer Bio during the 3rd quarter worth about $67,000. Finally, Algert Global LLC bought a new stake in Gossamer Bio during the 2nd quarter worth about $75,000. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.